Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07114653

The Role of POLE Mutation in High Risk Endometrial Cancer.

The actual role of POLE mutations in high-risk endometrial cancer is undetermined. The main question it aims to answer is:

What is the prevalence of POLE mutations in high-risk endometrial cancer case? What is the impact of POLE mutations in real world high-risk endometrial cancer case?

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Endometrial Neoplasms Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Genital Diseases Genital Diseases, Female Genital Neoplasms, Female Neoplasms Neoplasms by Site Urogenital Diseases Urogenital Neoplasms Uterine Diseases Uterine Neoplasms

Sex eligibility

Female

Study type

Observational

Primary location

Department of Obstetrics and Gynecology, Far Eastern Memorial Hospital

Banqiao District, New Taipei, 22050, Taiwan

Location status: Recruiting

Location contact

Sheng-Mou Hsiao, MD

CONTACT

[email protected]

+886-2-89667000 ext. 1818

About this study

All high-risk recurrent endometrial cancer cases who were treated in a tertiary referral center will be analyzed and subjected to POLE mutation analysis. In addition, survival analysis will be used to analyze the role of POLE mutations in women with high-risk endometrial cancer. We can answers the following.

  • What is the prevalence of POLE mutations in women with high-risk endometrial cancer?
  • What is the role of POLE mutations in real world high-risk endometrial cancer?

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • women with high-risk for recurrent endometrial cancer

Exclusion criteria

  • Nil

Treatment and study plan

Primary outcomes

  1. Prevalence of POLE mutation in high risk endometrial cancer

    Time frame: 2 years

    The prevalence of POLE mutations in women with high-risk for recurrent endometrial cancer

Secondary outcomes

  1. The impact of POLE on overall survival

    Time frame: 5 years

    The impact of POLE on overall survival, compared with the other TCGA groups

Sponsors and collaborators

Lead sponsor

Far Eastern Memorial Hospital

Other

Registry information

Important dates

Study start
2025
Primary completion
2026
Study completion
2026
First posted
Aug 11, 2025
Registry last updated
Aug 11, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.